ChartRow logo
Data provided bySource: Twelve Data
MDGL
$421.99-0.46%
as of close, Nov 17, 2026
☾ AH $421.99 -0.46%
Share this page

MDGL — Madrigal Pharmaceuticals Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in MDGL be worth today? →
MDGL returns: By year · By month · By week · Trailing

Price data

Price
$421.99
YTD price return
-27.54%
YTD total return
-27.54%
Market cap
9.8B
Enterprise value
9B
Shares outstanding
23.2M
52W low
$353.54
52W high
$615.00
From 52W high
-31.38%
From 52W low
+19.36%
52W range
26%$354–$615
Beta
-0.97

Volume

Rel volume
0.72×
30D volume
506.5K
30D $ vol
215.7M

Insider trading

Insider net 1W
none
Insider net 1M
+$34.6M
Insider net 3M
+$28.4M
Insider net 1Y
−$5.6M

Form 4 transactions by trade date, as filed; latest on file 2026-11-06.

Fundamentals

Sales (ttm)
1.4B
Sales/share
$61.47
EPS (ttm)
-$5.13
FCF (ttm)
-168.7M
FCF/share
-$7.26
Book value/share
$26.99
Net margin
-10.89%
ROE
-24.80%
ROA
-10.84%
Debt / equity
0.54×
Current ratio
3.05

Growth (CAGR, ttm) · 10Y

Sales
+92.88%n/an/an/a
Shares
+2.28%+5.57%+6.32%+7.22%

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+88.58%n/an/an/a
Book value/share
-2.04%+188.17%+14.46%+23.58%
Price
-23.76%+33.67%+37.16%+38.07%
Total return
-23.76%+33.67%+37.16%+38.07%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-82.3×
Fwd P/E
37.6×
P/S (ttm)
6.9×
P/B (mrq)
15.6×
EV/Sales (ttm)
6.3×
FCF yield (ttm)
-1.72%
Buyback yield (realized, 1y)
-2.28%
Shareholder yield (realized, 1y)
-2.28%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/B
75th

Bar = where today’s multiple sits in MDGL’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
-0.46%
5D
-2.45%
1M
-6.17%
3M
-19.60%
YTD
-27.54%
1Y
-23.75%
5Y
+385.27%
1D
-0.46%
5D
-2.45%
1M
-6.17%
3M
-19.60%
YTD
-27.54%
1Y
-23.75%
5Y
+385.27%

Fundamentals#

Revenue

5Y n/m5Y n/mYoY +50.1%
$1.4B TTM$431.3M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y n/mYoY n/m
−$152.7M TTM$56M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$5.13 TTM$1.83 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m10Y n/mYoY +47.6%
−$168.7M TTM$116.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow −$157M, capex −$11.6M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $120.6M, capex −$3.9M

Shares (diluted)

5Y +45.2%5Y +45.2%YoY +6.3%
30.3M TTM30.3M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y n/mYoY n/m
−$155.5M TTM$55.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full MDGL financials →

About Madrigal Pharmaceuticals#

Data provided bySource: Twelve Data

Madrigal Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need. Its lead product, Rezdiffra, is a once-daily oral therapy designed to address the underlying biology of MASH in adults with moderate to advanced liver fibrosis. The company’s current business is centered on liver disease, with a commercial presence supported by medical affairs, patient support, and market access activities. Madrigal Pharmaceuticals Inc. also maintains research and clinical development efforts around thyroid hormone receptor-beta science, reinforcing its role as a specialist company in hepatology and metabolic medicine. Based in West Conshohocken, Pennsylvania, Madrigal Pharmaceuticals Inc. serves a focused segment of the biopharmaceutical market that targets chronic liver and metabolic disorders.

West Conshohocken, PA·915 employees·Biotechnology·madrigalpharma.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding MDGL#

19 of the 193 ETFs ChartRow carries live hold MDGL. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
XBISPDR S&P Biotech ETF1.1%
IBBiShares Biotechnology ETF0.9%
VBKVanguard Small-Cap Growth ETF0.3%
IWPiShares Russell Mid-Cap Growth ETF0.3%
VBVanguard Small-Cap ETF0.1%
VXFVanguard Extended Market ETF0.1%
VHTVanguard Health Care ETF0.1%
IWRiShares Russell Midcap ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%